Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19
Fundamental & Clinical Pharmacology · 2024
DOI: 10.1111/fcp.12989 ↗Kurz gefasst
Fachartikel in der Zeitschrift Fundamental & Clinical Pharmacology, 2024. Verfasst von Liyan Zeng und 7 weiteren Autor:innen. Beteiligte Einrichtung: Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China. Hauptthemen laut MEDLINE: COVID-19 Drug Treatment, Ritonavir. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 31 Literaturangaben. Gefördert von: Science and Technology Plan Project of Zhejiang, Shanghai "Medical Garden Rising Star" Youth Medical Talent Training Funding Program, Shanghai Municipal Hospital Development Center.
Abstract (Originalsprache)
Background
The pharmacokinetic (PK) and pharmacodynamic (PD) characteristics of nirmatrelvir (NMV) are unknown in Chinese patients with COVID‐19.
Objectives
To understand the PK, as well as PK–PD characteristics of NMV for optimizing the dose in Chinese patients with COVID‐19.
Methods
We enrolled 141 participants who received NMV 300 mg/ritonavir (RTV) 100 mg b.i.d. for 5 days. The NMV concentrations were analyzed using 251 blood samples. PK/PD of NMV was investigated in these COVID‐19 patients using a nonlinear mixed‐effects model.
Results
The patients had a mean age of 82 years (range, 34–97). The absorption rate constant and apparent clearance of NMV in this Chinese cohort were 0.253 h −1 and 6.83 L/h, respectively, similar to Caucasian patients. No covariates affected NMV clearance. Predicted peak ( C max ) and trough concentration ( C min ) under 300 mg NMV/100 mg RTV b.i.d. were 4004 and 1498 ng/mL, respectively. Although higher AUC and C min were weakly associated with a slight increase in the number of cycle threshold (CT) of viral genes, no significant correlation was found, indicating a weak relationship between drug exposure and efficacy (CT).
Conclusions
In all, our findings suggest no ethnic PK differences, a weak and clinically insignificant relationship between drug exposure and efficacy, suitable dosage for Chinese patients (including the elderly) based on PK parameters, and the need for further studies to determine optimal regimens for high‐risk patients due to inter‐individual variability.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Clinical Research Center, Shanghai Public Health Clinical Center, Fudan University, Shanghai, China.
- Department of Pharmacy, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, China.
ORCID-Profile: Lijun Zhang
Förderung
- Science and Technology Plan Project of Zhejiang
- Shanghai "Medical Garden Rising Star" Youth Medical Talent Training Funding Program
- Shanghai Municipal Hospital Development Center
Zitieren
APA
Zeng, L., Chen, R., Jiang, X., Li, F., Zhu, Z., Jiao, Z., Ling, Y., & Zhang, L. (2024). Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19. Fundamental & Clinical Pharmacology. https://doi.org/10.1111/fcp.12989
Vancouver
Zeng L, Chen R, Jiang X, Li F, Zhu Z, Jiao Z, et al. Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19. Fundamental & Clinical Pharmacology. 2024. doi:10.1111/fcp.12989
BibTeX
@article{Zeng2024,
author = {Zeng, Liyan and Chen, Rui and Jiang, Xuhua and Li, Feng and Zhu, Zhaoqin and Jiao, Zheng and Ling, Yun and Zhang, Lijun},
title = {Population pharmacokinetics and pharmacodynamics of nirmatrelvir in Chinese patients with COVID‐19},
journal = {Fundamental & Clinical Pharmacology},
year = {2024},
doi = {10.1111/fcp.12989}
}
EUVIMED